In particular, Zugazagoitia and colleagues reported the identification of a novel panel of 12 biomarkers predictive of clinical response to an anti-PD1 checkpoint blockade in NSCLC patients using DSP technology, independently of conventional clinical prognostic factors [89]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.